Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• RAS-pathway mutations are common in myeloid malignancies.
• Data on RAS-pathway mutations in myelofibrosis (MF) is limited.

Purpose of the Study:

• To investigate the significance of RAS-pathway mutations in patients with MF.
• To evaluate the association of RAS mutations with clinical and molecular features and patient outcomes.

Main Methods:

• Analysis of next-generation sequencing data from 723 MF patients across three international centers.
• Evaluation of 16 genes, including RAS-pathway genes (NRAS/KRAS).
• Statistical analysis including multivariate Cox models and development of a novel predictive score.

Main Results:

• NRAS/KRAS variants were found in 6% of MF patients, often sub-clonal.
• RAS mutations correlated with advanced MF features like leukocytosis, high somatic mutation burden, and molecular high-risk mutations.
• MF patients with RAS mutations had significantly shorter overall survival (OS) and a higher incidence of acute myeloid leukemia (AML).
• RAS mutations were independently associated with decreased OS in a multivariate model.
• A novel predictive score incorporating RAS mutations demonstrated OS prediction capabilities.

Conclusions:

• RAS-pathway mutations are significant prognostic markers in myelofibrosis.
• Identification of RAS mutations is important for risk stratification and management of MF patients.
• Further research may explore therapeutic strategies targeting RAS mutations in MF.